Shots:
- SanegeneBio has entered into a global research & licensing deal with Eli Lilly to advance RNAi candidates for metabolic diseases, leveraging SanegeneBio’s LEAD (Ligand & Enhancer Assisted Delivery) tech
- Under the deal, SanegeneBio will discover & identify LEAD-based RNAi molecules for each program, while Lilly will oversee IND-enabling studies, clinical development, & commercialization; the platform enables SC therapies for metabolic diseases dosed as infrequently as twice per year
- As per the terms, SanegeneBio will receive upfront, equity investment, & near-term milestone payments, plus ~$1.2B in discovery, development, regulatory, & commercial milestones, as well as tiered royalties on future sales
Ref: PRNewswire| Image: SanegeneBio & Eli Lilly | Press Release
Related News:- Ailux Collaborates with Eli Lilly to Accelerate Bispecific Antibody Development
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
